% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Sprute:157614,
author = {K. Sprute and V. Kramer and S. Koerber and M. Meneses and
R. Fernandez and C. Soza-Ried and M. Eiber and W. Weber and
I. Rauscher and K. Rahbar and M. Schaefers and T. Watabe and
M. Uemura and S. Naka and N. Nonomura and J. Hatazawa and C.
Schwab and V. Schütz and M. Hohenfellner and T.
Holland-Letz$^*$ and J. Debus and C. Kratochwil and H.
Amaral and P. L. Choyke and U. Haberkorn and C. Sandoval and
F. L. Giesel},
title = {{D}iagnostic accuracy of 18{F}-{PSMA}-1007-{PET}/{CT}
imaging for lymph node staging of prostate carcinoma in
primary and biochemical recurrence.},
journal = {Journal of nuclear medicine},
volume = {62},
number = {2},
issn = {2159-662X},
address = {New York, NY},
publisher = {Soc.},
reportid = {DKFZ-2020-01711},
pages = {208-213},
year = {2021},
note = {2021 Feb;62(2):208-213},
abstract = {Purpose: Prostate specific membrane antigen (PSMA) -ligand
PET/CT is performed in patients with prostate cancer to
stage the disease initially or to identify sites of
recurrence after definitive therapy. 18F-PSMA-1007 is a
promising PSMA-PET tracer based on clinical results, but
detailed histologic confirmation has been lacking.
Experimental Design: 96 patients with prostate cancer
received a 18F-PSMA-1007-PET/CT followed by either radical
prostatectomy with lymphadenectomy or salvage
lymphadenectomy. The histological findings of
PSMA-PET-positive nodes were analysed retrospectively. A
lesion and a patient-based analysis was performed comparing
1) all positive and 2) only lesions with a size larger than
3 mm in histopathology. Results: $90.6\%$ of the patients
received 18F-PSMA-1007-PET/CT for staging before the primary
treatment, while 9.4 $\%$ of the cohort underwent imaging
for biochemical recurrence. In $34.4\%$ of the cohort
positive lymph nodes were present in imaging. A total of
1746 lymph nodes were dissected in 96 patients.
18F-PSMA-1007-PET had a lesion-based sensitivity of $81.7\%$
a specificity of $99.6\%,$ a positive predictive value (PPV)
of $92.4\%,$ a negative predictive value (NPV) of $98.9\%$
for detecting positive lymph nodes larger than 3 mm. In the
analysis of all malignant nodes regardless the size the
overall sensitivity, specificity, PPV, and NPV on
lesion-based analysis was $71.2\%,$ $99.5\%,$ $91.3\%,$ and
$97.9\%,$ respectively. The patient-based analysis showed a
sensitivity of $85.9\%$ and a specificity of $99.5\%$ for
lymph nodes >3 mm. Conclusion:18F-PSMA-1007-PET/CT reliably
detects malignant lymph nodes and has an exceptional
specificity of $>99\%$ for nodal metastases.},
cin = {C060},
ddc = {610},
cid = {I:(DE-He78)C060-20160331},
pnm = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
pid = {G:(DE-HGF)POF4-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:32817141},
doi = {10.2967/jnumed.120.246363},
url = {https://inrepo02.dkfz.de/record/157614},
}